News & articles

(PR)JAKAVI® the first medication to receive Health Canada approval to treat patients with myelofibrosisCanada Newswire (July 5, 2012 8:00 AM) • Myelofibrosis is a life-threatening blood cancer associated with progressive, debilitating symptoms that can severely impact quality of life and shorten survival • PRJAKAVI® (ruxolitinib tablets) approval is based on results from the most extensive… Read More »JAKAVI APPROVED IN CANADA

Effective July 2012, United Health Care now covers Peginterferon Alfa-2a (Pegasys) for treatment of myeloproliferative neoplasms Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (MF).  The change in UHC’s coverage policy resulted from a request by the MPN Research Foundation to amend its policy on Pegasys in light of the recent clinical trials showing the significant effectiveness… Read More »UNITED HEALTH CARE APPROVES PEGASYS FOR MPN

Phase 3 Study in Patients with Myelofibrosis and Low Platelet Counts Targetedto Start in Q4-2012 June 4, 2012, Seattle—Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC), announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.’s (“S*BIO”) pacritinib. Pacritinib is a highly selective oral JAK2 (Janus Associated Kinase 2) inhibitor… Read More »CELL THERAPEUTICS COMPLETES ACQUISITION OF PACRITINIB A HIGHLY SELECTIVE JAK2 INHIBITOR

The MPN Research Foundation is pleased to announce the creation of MPN Advocacy International, a new organization founded by former VP of Development Ann Brazeau. MPN Advocacy International will focus on outreach and education for people living with ET, PV and MF. On May 2nd they will host their first event, an educational symposium which will take place in… Read More »MPN ADVOCACY INTERNATIONAL

Today is February 29th – a day that comes every four years. It’s also Rare Disease Day. As you may know, Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis are designated rare diseases. In recognition we wanted to draw your attention to news for the Myeloproliferative Neoplasms community. • The National Organization for Rare Disorders has organized a campaign… Read More »RARE DISEASE DAY 2012

February 25, 2012 One of the biggest challenges facing the MPN Research Foundation in its mission to broaden and accelerate MPN research is raising enough dollars to really make a difference. With NIH and other sources cutting back on funding for medical research in general, our contribution to MPN science and scientists becomes more and… Read More »BIOTECH AND PHARMACEUTICAL JOIN THE FIGHT TO FUND MORE MPN RESEARCH

With funding in part by the MPN Research Foundation, researchers at Mayo Clinic in Arizona have developed a symptom assessment tool for people with Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. Dr. Ruben Mesa created a way to accurately measure the types and severity of symptoms suffered by patients with one of the myeloproliferative neoplasms (MPNs). Dr. Mesa has been… Read More »RUBEN MESA’S SYMPTOM ASSESSMENT TOOL HELPS PATIENTS WITH MPN

Click here to be directed to the article from Mayo Proceedings Click here to watch the video of Dr. Tefferi describing the study

2011 Benjamin Ebert, MD & Ross L. Levine, MD Harvard Medical School & Memorial Sloan-Kettering Cancer CenterProject Title: “Whole Genome Sequencing to Identify Germline and Somatic Disease Alleles Which Contribute to MPD Pathogenesis“ Two central goals for elucidating the biology of myeloproliferative disease are the characterization of the full complement of somatic mutations that cause MPD,… Read More »SELECTED ABSTRACTS FUNDED BY MPD FOUNDATION 2000-PRESENT, PRESENTED IN CHRONOLOGICAL ORDER

S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF) -S*BIO Explores Partnering Opportunities for Advancement of its Leading JAK2 Program- SINGAPORE, Oct. 25, 2011 – S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib… Read More »SBIO JAK2 INHIBITOR CLINICAL TRIALS OCTOBER 2011